<DOC>
	<DOCNO>NCT02144857</DOCNO>
	<brief_summary>Psoriasis associate increase risk atherosclerosis . The investigator investigate whether surrogate marker subclinical atherosclerosis , vascular dysfunction myocardial dysfunction impair patient psoriasis compare normal control , coronary artery disease patient untreated hypertension subject . The investigator also examine effect treatment biological v biological agent vascular LV function psoriasis .</brief_summary>
	<brief_title>Effects Treatment With Biological Agents Vascular Cardiac Function Psoriasis</brief_title>
	<detailed_description>The investigator compare patient psoriasis age sex match normal control well patient angiographically document CAD patient untreated hypertension ( HYP ) use positive control group Patients psoriasis ( PS ) randomize receive anti-tumor necrosis-a ( TNF-a ) , anti- interleukin 12/23 regimen cyclosporine regimen . The anti-TNF-agent , Etanercept give dose 50mg twice weekly 12 week weekly . The anti-IL12/23 regimen , Ustekinumab give dose 45 mg first visit , 4 week every 12 week body weight 90 kgr . For body weight &gt; 90kgr dose adjust accordingly . Cyclosporine administer dose 2.5-3mg/kgr daily . At baseline , 12 week one year treatment , investigator measure : 1. pulse wave velocity ( PWVc ) augmentation index ( AI ) central systolic blood pressure ( cSBP ) ( Complior , Alam Medical Arteriograph , TensioMed ) 2. flow-mediated dilation brachial artery ( FMD ) 3. carotid intima-media thickness ( IMT ) ultrasonography 4. coronary flow reserve LAD ( CFR ) Doppler echocardiography 5 . E'/A mitral annular velocity , LV longitudinal ( GLS - % ) , strain , strain rate ( LongSr-l/s ) , peak twisting ( Tw -deg ) , peak twisting ( Tw-deg/sec ) velocity , untwist mitral valve open ( unTw ) untwisting ( unTw ) velocity use speckle track echocardiography . 6 . Perfused boundary region ( PBR ) sublingual arterial microvessels ( range 5-25 micron ) use Sideview Darkfield imaging . ( Microscan , Glycocheck ) .The PBR microvessels cell-poor layer result phase separation flow red blood cell ( RBC ) plasma.The PBR include luminal part glycocalyx allow cell penetration . Increased PBR consider accurate index reduce endothelial glycocalyx thickness deeper RBC penetration glycocalyx . 7 . Fetuin serum level , marker oxidative stress malondialdehyde ( MDA ) serum level , protein carbonyl aw well thrombosis inflammation biomarkers</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>patient psoriasis Age sex match patient CAD , untreated hypertension healthy subject psoriasis patient presence wall motion abnormality ejection fraction ≤ 50 % , psoriatic arthritis , history acute coronary syndrome , familial hyperlipidemia , insulin dependentdiabetes mellitus , chronic obstructive pulmonary disease asthma , moderate severe valvular heart disease , primary cardiomyopathy malignant tumor . CAD exclude psoriasis patient absence clinical history , angina reversible myocardial ischemia , assess dobutamine stress echocardiography thallium scintigraphy regard group CAD patient , include patient without history ST elevation myocardial infarction order exclude presence transmural scar compromise myocardial function index . Thus , CAD patient wall motion abnormality ejection fraction ≤ 50 % exclude . In addition , exclusion criterion , history acute coronary syndrome without STsegment elevation within last year , familial hyperlipidemia , insulin dependentdiabetes mellitus , chronic obstructive pulmonary disease asthma , moderate severe valvular heart disease , primary cardiomyopathy malignant tumor normal control , CAD exclude presence normal ECG , absence clinical history absence reversible ischemia mean treadmill test dobutamine stress echocardiography</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>